November 11, 2024 06:30 AM EST
Cell/Gene Tx
Law

Cell ther­a­py star­tup's IPO plans thrown in lim­bo amid le­gal spat with in­vestor Al­con

Andrew Dunn

Senior Biopharma Correspondent

The eye gi­ant Al­con has launched an un­like­ly le­gal bat­tle, su­ing a cell ther­a­py start­up that it in­vest­ed in and claim­ing its share­hold­er rights are …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

FDA ap­proves Io­n­is’ treat­ment for a rare meta­bol­ic dis­or­der

A service from the Financial Times